<DOC>
	<DOCNO>NCT02150525</DOCNO>
	<brief_summary>This randomize double-blind clinical trial study effect oral omega-3 fatty acid atrophic vaginitis postmenopausal breast cancer survivor ( N=52 ) . Omega-3 fatty acid may reduce inflammation improve vaginal symptom postmenopausal breast cancer survivor .</brief_summary>
	<brief_title>Effect Omega 3 Atrophic Vaginitis Breast Cancer Survivors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To examine ability oral omega-3 fatty acid improve symptom atrophic vaginitis report postmenopausal breast cancer survivor compare survivor take omega 3 . II.To examine ability oral omega-3 fatty acid decrease inflammation relate atrophic vaginitis postmenopausal breast cancer survivor compare survivor take omega 3 . III . To examine ability oral omega-3 fatty acid uptake systemically validate adherence ; measure compare demographic data include body mass index observe difference exist postmenopausal breast cancer survivor vs. take omega 3 . IV . To examine effect oral omega 3 fatty acid compare placebo dietary supplement serum female hormone level postmenopausal breast cancer survivor . V. To examine cytokine level woman take oral omega 3 fatty acid compare woman take omega 3 determine effect . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive 3.5g omega-3 fatty acid orally ( PO ) daily 6 month . ARM II : Patients receive placebo dietary supplement ( 7 capsule ) PO daily 6 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<criteria>Woman history breast cancer , stage 0 , I , II , III At least 12 month definitive surgical procedure ( i.e . lumpectomy mastectomy ) At least 3 month completion chemotherapy Postmenopausal , define menstrual cycle 12 consecutive month , surgical menopause Have one state symptom atrophic vaginitis , vaginal dryness , genital irritation/itching , genital pain , and/or dyspareunia No current use estrogen replacement therapy If recent use estrogen replacement therapy , least three month No current use estradiolreleasing vaginal ring estradiol vaginal tablet ; recent use product , least 3 consecutive month No evidence disease ( NED ) , cancer breast cancer No current use oral omega 3 fatty acid Vitamin E ; recent consistent use product , least six month ; sporadic use product , least 3 consecutive month May take oral antiestrogens aromatase inhibitor , and/or biologic therapy Must willing undergo venipuncture 0 , 3 , 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 No history bleed tendency No history uncontrolled hypertension , heart disease stroke Hemoglobin &gt; 10 g/dL Hematocrit &gt; 30 % White blood count &gt; 3.5 K/uL Platelet count &gt; 100,000/mm^3 Fasting serum glucose &lt; 115 mg/dL Total bilirubin &lt; 1.6 mg/dL Transaminases alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 1.5 x ULN ( upper limit normal ) Metastatic malignancy kind Ongoing chemotherapy radiation therapy ( ongoing hormonal therapy and/or biologic therapy allow ) History pelvic genital radiation therapy Use Coumadin anticoagulant Known , active pelvic , vaginal , urinary tract infection Current use hormone replacement therapy , either systemic local Uncontrolled comorbidities include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , unstable hypertension Psychiatric illness/social situation would limit adherence study requirement Consistent use omega3 fatty acid concentrate capsule within 6 month prior entry study Known sensitivity allergy fish oil omega 3 fish product Pregnant nursing woman Subjects give inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>vaginal dryness</keyword>
	<keyword>dyspareunia</keyword>
	<keyword>genital irritation</keyword>
</DOC>